PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY
PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY
复制标题
DOI：
10.7326/0003-4819-122-4-199502150-00003
复制
发表时间：
1995-02-15
影响因子：
39.2
通讯作者：
KEATING, MJ
中科院分区：
文献类型：
--
作者：
KANTARJIAN, HM;SMITH, TL;KEATING, MJ
目的：确定慢性粒细胞白血病患者接受干扰素 α 治疗后的细胞遗传学反应是否与生存率改善独立相关。设计：回顾性分析。患者：1982 年至 1990 年间，274 名诊断为费城染色体阳性慢性粒细胞白血病早期慢性期患者接受基于干扰素 α 的治疗。干预：每日 5 点皮下注射干扰素 α 治疗。 x 10(6) U/m(2) 体表面积（研究允许的最高剂量方案）或最大耐受的较低剂量方案。结果：总体而言，219 名 (80%) 患者实现了完全血液学缓解，104 名 (38%) 患者实现了主要细胞遗传学缓解（
Objective: To determine whether a cytogenetic response after interferon-alpha therapy in patients with chronic myelogenous leukemia is independently associated with improved survival.Design: Retrospective analysis.Patients: 274 patients with a diagnosis of Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase who were treated with interferon-alpha-based programs between 1982 and 1990.Intervention: Therapy with daily subcutaneous interferon-alpha given at 5 x 10(6) U/m(2) body surface area (highest dose schedule allowed on studies) or the maximally tolerated lower-dose schedule.Results: Overall, 219 (80%) patients achieved a complete hematologic response and 104 (38%) achieved a major cytogenetic response (